View Past PerformancePing An Biomedical バランスシートの健全性財務の健全性 基準チェック /46Ping An Biomedicalの総株主資本はCN¥45.2M 、総負債はCN¥10.0Mで、負債比率は22.1%となります。総資産と総負債はそれぞれCN¥68.4MとCN¥23.2Mです。主要情報22.10%負債資本比率CN¥10.00m負債インタレスト・カバレッジ・レシオn/a現金CN¥1.17mエクイティCN¥45.24m負債合計CN¥23.17m総資産CN¥68.41m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 10Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026, at 09:00 China Standard Time. Location: 7/f, china united plaza, 1002-1008, tai nan west street, cheung sha wan, kowloon Hong KongReported Earnings • Feb 01Full year 2025 earnings released: CN¥0.69 loss per share (vs CN¥0.071 loss in FY 2024)Full year 2025 results: CN¥0.69 loss per share (further deteriorated from CN¥0.071 loss in FY 2024). Revenue: CN¥34.1m (down 61% from FY 2024). Net loss: CN¥12.8m (loss widened CN¥11.5m from FY 2024).お知らせ • Jan 10Ping An Biomedical Co., Ltd. announced a financing transactionPing An Biomedical Co., Ltd. entered into a Securities Purchase Agreement and announced a private placement January 9, 2026. The transaction involves participation from individual investors Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd; and Li Daxue, Chairman and CEO of Magcloud Group Co., Ltd and former Senior Vice President of JD.com and its Lifetime Honorary Advisor.New Risk • Jan 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Minor Risks Market cap is less than US$100m (US$12.7m market cap).New Risk • Nov 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.56m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Market cap is less than US$10m (US$9.56m market cap). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change).Board Change • Nov 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Jifeng Gao is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 05First half 2025 earnings released: CN¥0.23 loss per share (vs CN¥0.013 profit in 1H 2024)First half 2025 results: CN¥0.23 loss per share (down from CN¥0.013 profit in 1H 2024). Revenue: CN¥18.2m (down 60% from 1H 2024). Net loss: CN¥4.23m (down CN¥4.47m from profit in 1H 2024).Buy Or Sell Opportunity • Oct 01Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at US$0.98. The fair value is estimated to be US$1.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 14% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Sep 05Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at US$1.08. The fair value is estimated to be US$1.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making.Board Change • Aug 12High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Buy Or Sell Opportunity • Aug 06Now 27% overvaluedThe stock has been flat over the last 90 days, currently trading at US$1.75. The fair value is estimated to be US$1.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Jul 18Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million.Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: $6 Discount Per Security: $0.42Board Change • Jul 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.財務状況分析短期負債: PASWの 短期資産 ( CN¥63.7M ) が 短期負債 ( CN¥23.1M ) を超えています。長期負債: PASWの短期資産 ( CN¥63.7M ) が 長期負債 ( CN¥95.7K ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: PASWの 純負債対資本比率 ( 19.5% ) は 満足できる 水準であると考えられます。負債の削減: PASWは 5 年前には株主資本がマイナスでしたが、現在はプラスになっており、改善されています。債務返済能力: PASWの 営業キャッシュフロー はマイナスであるため、負債は十分にカバーされていません。インタレストカバレッジ: PASWの負債に対する 利息支払い が EBIT によって 十分にカバーされている かどうかを判断するにはデータが不十分です。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YRetail 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 23:35終値2026/05/27 00:00収益2025/09/30年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ping An Biomedical Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 10Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026Ping An Biomedical Co., Ltd., Annual General Meeting, Mar 18, 2026, at 09:00 China Standard Time. Location: 7/f, china united plaza, 1002-1008, tai nan west street, cheung sha wan, kowloon Hong Kong
Reported Earnings • Feb 01Full year 2025 earnings released: CN¥0.69 loss per share (vs CN¥0.071 loss in FY 2024)Full year 2025 results: CN¥0.69 loss per share (further deteriorated from CN¥0.071 loss in FY 2024). Revenue: CN¥34.1m (down 61% from FY 2024). Net loss: CN¥12.8m (loss widened CN¥11.5m from FY 2024).
お知らせ • Jan 10Ping An Biomedical Co., Ltd. announced a financing transactionPing An Biomedical Co., Ltd. entered into a Securities Purchase Agreement and announced a private placement January 9, 2026. The transaction involves participation from individual investors Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd; and Li Daxue, Chairman and CEO of Magcloud Group Co., Ltd and former Senior Vice President of JD.com and its Lifetime Honorary Advisor.
New Risk • Jan 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Minor Risks Market cap is less than US$100m (US$12.7m market cap).
New Risk • Nov 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.56m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CN¥12m). Earnings have declined by 67% per year over the past 5 years. Market cap is less than US$10m (US$9.56m market cap). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change).
Board Change • Nov 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Jifeng Gao is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 05First half 2025 earnings released: CN¥0.23 loss per share (vs CN¥0.013 profit in 1H 2024)First half 2025 results: CN¥0.23 loss per share (down from CN¥0.013 profit in 1H 2024). Revenue: CN¥18.2m (down 60% from 1H 2024). Net loss: CN¥4.23m (down CN¥4.47m from profit in 1H 2024).
Buy Or Sell Opportunity • Oct 01Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at US$0.98. The fair value is estimated to be US$1.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 14% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Sep 05Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at US$1.08. The fair value is estimated to be US$1.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making.
Board Change • Aug 12High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Buy Or Sell Opportunity • Aug 06Now 27% overvaluedThe stock has been flat over the last 90 days, currently trading at US$1.75. The fair value is estimated to be US$1.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Jul 18Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million.Majestic Ideal Holdings Limited has completed an IPO in the amount of $15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: $6 Discount Per Security: $0.42
Board Change • Jul 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Co-Founder & Chairperson of the Board Judy Li was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.